Tiziana Life Sciences Ltd TLSA
0.66 USD +0.05 (+7.44%)
Nov 11, 2026, 12:54 PM EST
0.61 Day range 0.6564
0.57 52-week range 1.90
- YTD
- -56.00%
- 1 year
- -62.32%
News
seekingalpha.com Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript
benzinga.com Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
globenewswire.com Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
benzinga.com Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as…- benzinga.com Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…- benzinga.com Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com Tiziana Completes Phase 2a MS Trial, Topline Data Due In October Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com Why Is Tiziana Life Sciences Stock Gaining Thursday? Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07%…
benzinga.com This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
benzinga.com BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7 BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.- benzinga.com Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
benzinga.com Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative…
benzinga.com Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026 Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary…- benzinga.com Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per Share Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal…
- benzinga.com Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that…
- benzinga.com Tiziana Life Sciences' Updated Data From Its Ongoing Expanded Access Program Of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis Shows Encouraging Trends In Stabilization Of Disability And Meaningful Improvements In Fatigue Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated…
benzinga.com Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of Forlumab Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial…- benzinga.com Tiziana Life Sciences Announces Publication Of Preclinical Data Showing Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation And Improves Cognitive Function Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.
- benzinga.com 30 Stocks Moving in Friday's Pre-Market Session
- benzinga.com 80 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
- benzinga.com 34 Stocks Moving In Tuesday's Mid-Day Session Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor…
- benzinga.com 65 Biggest Movers From Yesterday Gainers
- benzinga.com 46 Stocks Moving In Thursday's Mid-Day Session Gainers Sphere 3D Corp. (NASDAQ: ANY) shares surged 36% to $9.02 as traders circulate a tweet from popular Twitter trader Will Meade saying 'Long $ANY this is the next $SPRT and they have a very good…
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday morning, 136 companies reached new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 207 companies hit new 52-week lows.
- benzinga.com 45 Biggest Movers From Yesterday Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.